EAM
CRL icon

Eagle Asset Management’s Charles River Laboratories CRL Stock Holding History

Eagle Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-208,086
Closed -$45.4M – 549
2022
Q4 		$45.4M Sell
208,086
-262
-0.1% -$57.2K 0.28% 125
2022
Q3 		$41M Buy
208,348
+1,112
+0.5% +$240K 0.27% 122
2022
Q2 		$44.3M Buy
207,236
+52,656
+34% +$12.9M 0.28% 124
2022
Q1 		$43.9M Sell
154,580
-142,603
-48% -$44M 0.22% 142
2021
Q4 		$112M Buy
297,183
+523
+0.2% +$203K 0.49% 68
2021
Q3 		$122M Buy
296,660
+96,374
+48% +$40M 0.55% 58
2021
Q2 		$74.1M Sell
200,286
-3,218
-2% -$1.07M 0.32% 120
2021
Q1 		$59.9M Buy
203,504
+10,023
+5% +$2.79M 0.27% 142
2020
Q4 		$48.3M Buy
193,481
+50,082
+35% +$11.9M 0.27% 133
2020
Q3 		$32M Buy
143,399
+131,357
+1,091% +$27.3M 0.16% 186
2020
Q2 		$2.04M Sell
12,042
-28,307
-70% -$4.52M 0.01% 446
2020
Q1 		$5.09M Sell
40,349
-211
-0.5% -$31.6K 0.03% 360
2019
Q4 		$6.2M Sell
40,560
-3,162
-7% -$438K 0.03% 379
2019
Q3 		$5.79M Sell
43,722
-8,784
-17% -$1.18M 0.03% 381
2019
Q2 		$7.45M Sell
52,506
-6,011
-10% -$815K 0.04% 350
2019
Q1 		$8.5M Sell
58,517
-4,380
-7% -$575K 0.05% 323
2018
Q4 		$7.12M Buy
62,897
+60
+0.1% +$7.51K 0.04% 326
2018
Q3 		$8.45M Buy
62,837
+31,815
+103% +$3.93M 0.04% 362
2018
Q2 		$3.48M Buy
+31,022
New +$3.35M 0.02% 465
2018
Q1 		– Sell
-367,390
Closed -$39.9M – 632
2017
Q4 		$39.9M Buy
367,390
+46,049
+14% +$5.01M 0.22% 163
2017
Q3 		$35M Buy
321,341
+16,016
+5% +$1.65M 0.2% 172
2017
Q2 		$30.9M Buy
305,325
+13,223
+5% +$1.22M 0.19% 189
2017
Q1 		$26.3M Buy
+292,102
New +$24.8M 0.17% 185
2014
Q1 		– Sell
-66,055
Closed -$3.5M – 656
2013
Q4 		$3.5M Buy
66,055
+8,520
+15% +$428K 0.02% 499
2013
Q3 		$2.66M Buy
57,535
+10,175
+21% +$467K 0.01% 599
2013
Q2 		$1.94M Buy
+47,360
New +$2.03M 0.01% 609

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Eagle Asset Management's CRL Position: Q1 2023 in Review

Eagle Asset Management sold out of Charles River Laboratories (CRL) in Q1 2023, closing a stake of 208,086 shares — an estimated $45.4M sold.

Eagle Asset Management first reported a position in CRL in Q2 2013 and held it in 26 quarters. The position peaked at $122M in Q3 2021. 620 funds tracked by Wall St. Rank hold CRL as of Q1 2023.

  • Eagle Asset Management reported no remaining Charles River Laboratories position as of Q1 2023 after selling out during the quarter.
  • Eagle Asset Management sold 208,086 Charles River Laboratories shares in Q1 2023, an estimated $45.4M.
  • Eagle Asset Management first reported a position in Charles River Laboratories in Q2 2013 and held it in 26 quarters.
  • Eagle Asset Management's Charles River Laboratories position peaked at $122M in Q3 2021.
  • 620 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2023.

Based on Eagle Asset Management's 13F filing for Q1 2023, filed 8 May 2023.